Role of spleen or spleen products in the reduced locomotor-enhancing effect of morphine in diabetic mice.
In the present study, we examined the possibility that factor(s) derived from spleen cells are involved in the reduced morphine-induced hyperlocomotion in diabetic mice. The mean total locomotor activity after s.c. administration of morphine (20 mg/kg) in non-diabetic mice was significantly greater than that in diabetic mice. Splenectomized diabetic mice had a significantly higher sensitivity to morphine-induced hyperlocomotion than untreated or sham-operated diabetic mice. However, morphine-induced hyperlocomotion in non-diabetic mice was unaffected by splenectomy or sham-operation. Furthermore, 7 days after adoptive transfer of the supernatant of spleen cell homogenate (SSCH) from diabetic mice (SSCH-D), naive mice that had been injected with SSCH-D showed lower morphine-induced locomotor activity than mice which had been injected with SSCH from non-diabetic mice (SSCH-ND). These results suggest that some factor(s) derived from spleen cells may play an important direct or indirect role in the selective reduction of morphine's locomotor-enhancing effect in diabetic mice.
Kamei
J
J
Department of Pathophysiology and Therapeutics, Faculty of Pharmaceutical Sciences, Hoshi University, Tokyo, Japan.
Saitoh
A
A
D000818:Animals; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy*; D008124:Locomotion / Q000187:drug effects*; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D009020:Morphine / Q000494:pharmacology*; D009294:Narcotics / Q000494:pharmacology*; D017450:Receptors, Opioid, mu / Q000819:agonists; D013154:Spleen / Q000502:physiology* / Q000601:surgery; D013156:Splenectomy
D009294:Narcotics; D017450:Receptors, Opioid, mu; D009020:Morphine